Skip to Navigation
Skip to Content

NCSD Federal Policy Update - July 20, 2012

This week, the House Labor, Health and Human Services Appropriations Subcommittee marked up its fiscal year (FY) 2013 funding bill. As expected, due to the fact that the House’s top line funding level is $19 billion lower than the Senate’s top line number, funding for many programs were cut drastically from current funding levels. The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention took a $105 million cut from FY2012 funding. Further details on how that cut is broken down among the Divisions of the Center, including DSTDP and DASH, are not currently available. We are hoping to receive additional information during the House’s full Appropriations Committee markup of this bill, which is supposed to occur next week, but no formal date and time has been scheduled.

In non-funding news, on July 9, the President signed into law the Food and Drug Administration (FDA) Safety and Innovation Act, which included the Generating Antibiotic Incentives Now (GAIN) Act. As covered in previous NCSD Weekly Updates, NCSD is supportive of the GAIN Act because it creates incentives to encourage the development of products to treat, prevent, detect and diagnose antibiotic-resistant infections, which could help address the growing resistance of gonorrhea to antimicrobials. To learn more about the antibiotic provisions in the FDA law, please click here. NCSD thanks the Infectious Diseases Society of America for promoting the GAIN Act, with our support, and we look forward to working with them more in the future.

As always, if you have questions or concerns, please contact Stephanie Arnold Pang, NCSD’s Manager, Policy and Communications at sarnold@ncsddc.org or 202-715-3865.

Highlighted Resources

The National Coalition for Sexual Health (NCSH) is pleased to announce the release of a new, easy-to-use guide and website, Take Charge of Your Sexual Health: What you nee

Read more...

On December 19th, 2013, the American Sexual Health Association (ASHA) and the National Coalition of STD Directors (NCSD) convened a small group of stakeholders from the policy, research, cancer, healthcare provider and sexual health fields to discuss potential policy actions to facilitate HPV/Pap co-testing, and adherence to screening guidelines.

Read more...